Rifaximin

Kathryn Dzintars, Pharm.D., BCPS, Paul A. Pham, Pharm.D.

INDICATIONS

FDA

  • Treatment of traveler’s diarrhea due to noninvasive E. coli
  • Reduction in risk of overt hepatic encephalopathy recurrence
  • Treatment of Irritable Bowel Syndrome-diarrhea predominant (IBS-D)

NON-FDA APPROVED USES

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: March 7, 2019